spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použití této vakcíny musí být v souladu s oficiálními doporučeními.
erysin single shot 1 rp injekční emulze
bioveta, a.s. - erysipelothrix vakcíny - injekční emulze - 1rp - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - prasata
cytarabin kabi 100mg/ml injekční/infuzní roztok
fresenius kabi s.r.o., praha ČeskÁ republika - 1570 cytarabin - injekční/infuzní roztok - 100mg/ml - cytarabin
meropenem aptapharma 1000mg prášek pro injekční/infuzní roztok
apta medica internacional d.o.o., ljubljana array - 14052 trihydrÁt meropenemu - prášek pro injekční/infuzní roztok - 1000mg - meropenem
meropenem aptapharma 500mg prášek pro injekční/infuzní roztok
apta medica internacional d.o.o., ljubljana array - 14052 trihydrÁt meropenemu - prášek pro injekční/infuzní roztok - 500mg - meropenem
niontix 100% medicinální plyn, zkapalněný
linde gas a.s., praha array - 2473 oxid dusnÝ - medicinální plyn, zkapalněný - 100% - oxid dusnÝ
physioneal 40 clear-flex glucose 13,6 mg/ml roztok pro peritoneální dialýzu
baxter czech spol. s r.o., praha array - 4957 monohydrÁt glukosy; 5599 dihydrÁt chloridu vÁpenatÉho; 856 hexahydrÁt chloridu hoŘeČnatÉho; 1322 chlorid sodnÝ; 2178 hydrogenuhliČitan sodnÝ; 996 roztok natrium s laktÁtu - roztok pro peritoneální dialýzu - hypertonickÉ roztoky
physioneal 40 clear-flex glucose 22,7 mg/ml roztok pro peritoneální dialýzu
baxter czech spol. s r.o., praha array - 4957 monohydrÁt glukosy; 5599 dihydrÁt chloridu vÁpenatÉho; 856 hexahydrÁt chloridu hoŘeČnatÉho; 1322 chlorid sodnÝ; 2178 hydrogenuhliČitan sodnÝ; 996 roztok natrium s laktÁtu - roztok pro peritoneální dialýzu - hypertonickÉ roztoky
physioneal 40 clear-flex glucose 38,6 mg/ml roztok pro peritoneální dialýzu
baxter czech spol. s r.o., praha array - 4957 monohydrÁt glukosy; 5599 dihydrÁt chloridu vÁpenatÉho; 856 hexahydrÁt chloridu hoŘeČnatÉho; 1322 chlorid sodnÝ; 2178 hydrogenuhliČitan sodnÝ; 996 roztok natrium s laktÁtu - roztok pro peritoneální dialýzu - hypertonickÉ roztoky